This case is the first and only case in which a primary malignant melanoma developed from a mature teratoma of ovary while there was a concurrent primary endometrial carcinoma in uterus. Postsurgical histopathological examinations reveal concurrent primary ovarian and primary endometrial carcinoma at a rate of 5-15%, while the same rate climbs up to 30-40% in postmortem examinations[13-14].
The pelvic mass was removed completely. Histology of the frozen sections indicated the presence of a malignancy and a total abdominal hysterectomy, left salpingo-oophorectomy, pelvic-para-aortic lymphadenectomy, appendectomy and omentectomy was performed simultaneously. The right cystic ovarian mass that consisted of numerous solid brown areas and had a maximum diameter of 3.5 cm and was 14 cm in diameter was sent to the pathology laboratory (Figure 2).
Microscopic examination showed squamous epithelium, sebaceous glands, and hair follicles consistent with a mature cystic teratoma. In one area, atypical cells with melanin pigment deposition were seen underlying the epithelium. These cells displayed nuclear pleomorphism and increased mitotic activity. The tumor cells were positive for S100, Melan A, HMB45 and vimentin. The cells were negative for pancytokeratin and inhibin. The findings described above were most consistent with a diagnosis of malignant melanoma arising in a mature cystic teratoma (Figure 3AD).
Paraaortic lymph nodes displayed evidence of malignant melanoma metastasis. The left ovary, omentum and appendix were free of malignant melanoma involvement. In the tissue removed by the hysterectomy, a ‘welldifferentiated endometrioid carcinoma' that involved the inner half of the endometrial wall was found (Figure 4).
Figure 4: Photomicrograph shows well -differentiated endometrioid adenocarcinoma (H&E x100).
Postoperatively, interferon 2B and radiation therapy (RT) was administered. She received IFN-α 2B 5.000.000 U three days per week for two months. In addition, paraaortic and pelvic RT (4500 cGy) was administered for 25 days.
Concurrence of ovarian and endometrial malignancies may be classified in 3 groups: (a) metastasis of a primary endometrial carcinoma to ovary, (b) metastasis of a primary ovarian cancer to endometrium, and (c) concurrent primary ovarian and endometrial carcinomas. Clinical and histopathological characteristics of this patient suggested that the 2 tumors were separate, distinct malignancies and neither of two was a metastasis of the other. It is evident that the primary focus of the melanoma was the ovarian teratoma because of absence of a previous history of melanoma, absence of another melanoma focus on physical examination, and presence of melanoma solely in ovarian tissue. Nevertheless, there was no relationship between malignant ovarian melanoma and the concurrent well– differentiated endometrium cancer. We therefore considered both tumors as occurring together by coincidence.
Although, malignant melanoma primarily originating from ovary is very rare, postmortem examinations have revealed that 18% of extra-ovarian malignant melanoma cases have also tumor in ovary[1]. A comprehensive literature review revealed 37 cases of malignant melanoma originating from ovary. The first case dates back to 1901[6-12]. Cronge and Wooduff accepted absence of an extra-ovarian focus of malignant melanoma, presence of a focus of malignant melanoma in the same ovary harboring teratoma, and showing melanocyte junctional activity as diagnostic criteria for a primary ovarian malignant melanoma[17].
Primary ovarian melanoma is a tumor with a considerably malignant course and already has metastases at the time of diagnosis[18]. Treatment for epithelial malignancies originating from ovarian dermoid cysts is similar to that given for other ovarian malignancies, although optimal treatment has yet to be established[19]. Malignant melanoma has a substantially poorer prognosis compared to malignancies originating from superficial epithelium or dermoid cyst of ovary[20]. Treatment of primary melanoma consists of surgical excision including regional lymph nodes. Other additional therapies include radiation, chemotherapy and administration of chemoimmunotherapy. Alfa-interferon and interleukin 2 (immunotherapy) are promising new treatments for metastatic melanoma[21].
Postoperatively, our patient received combination IFN-α 2B and radiotherapy. Subsequently, she remained asymptomatic for 12 months. We have not detected serious side effect during the treatment. A combination of surgical debulking and immunotherapy may be of significant benefit in this rare disease.
1) Nogales FF. Germ cell tumours of the ovary. In: Fox H, Wells
M, editors. Haines and Taylor obstetrical and gynaecological
pathology. New York: Churchill Livingstone; 1995:847-96.
2) Stamp GW, McConnell EM. Malignancy arising in cystic ovarian
teratomas. A report of 24 cases. Br J Obstet Gynaecol. 1983; 90:
671-5.
3) M alkasian GD, Symmonds RE, Dockerty MB. Malignant ovarian
teratomas. Report of 31 cases. Obstet Gynecol. 1965; 25:810-4.
4) Hasleton PS, Kelehan P, Whittaker JS, Burslem RW, Turner L.
Benign and malignant struma ovarii. Arch Pathol Lab Med. 1978;
102:180-4.
5) Andrews HR. Primary melanotic sarcoma of the ovary. Trans
Obstet Soc (London). 1901; 43:228-31.
6) M cNeilage LJ, Morgan J, Constable J, Jobling TW. Metastatic
malignant melanoma arising in a mature ovarian cystic teratoma:
A case report and literature review. Int J Gynecol Cancer. 2005;
15:1148-52.
7) Watanabe Y, Ueda H, Nakajima H, Minoura R, Hoshiai H, Noda
K. Amelanotic malignant melanoma arising in an ovarian cystic
teratoma: A case report. Acta Cytol. 2001; 45:756-60.
8) M oehrle M, Fischbach H, Nuessle B, Rassner G. Primary
malignant melanoma arising in a cystic necrotic ovarian teratoma.
Eur J Obstet Gynecol Reprod Biol. 2001; 99:268-71.
9) O'Leary AJ, Tejura H. Malignant melanoma arising in a cystic
teratoma of the ovary. J Obstet Gynaecol. 2005; 25:626-7.
10) Dhorigol VM, Malur PR, Natu. Primary malignant melanoma of
the ovary a case report. Indian J Pathol Microbiol. 2005; 48:213-5.
11) Suneja A, Yadav P, Sharma A, Vaid NB, Singh B, Grover RK.
Primary malignant melanoma cystic teratoma of ovary. Indian J
Cancer. 2009; 46:340-2.
12) Lee SH, Lee KB, Shin JW, Chung DH, Park CY. An malignant
melanoma without evidence of teratoma. J Obstet Gynaecol Res.
2010; 36:898-901.
13) Eisner RF, Nieberg RK, Berek JS. Synchronous primary neoplasms
of the female reproductive tract. Gynecol Oncol. 1989; 33:335-9.
14) Kline RC, Wharton JT, Atkinson EN, Burke TW, Gershenson
DM, Edwards CL. Endometrioid carcinoma of the ovary:
Retrospective review of 145 cases. Gynecol Oncol. 1990; 39:337-
46.
15) U kah CO, Ikpeze OC, Eleje GU, Eke AC. Adult granulosa cell
tumor associated with endometrial carcinoma: A case report. J
Med Case Reports. 2011; 5: 340.
16) Gök ND, Yildiz K, Corakçi A. Primary malignant melanoma of
the ovary: Case report and review of the literature. Turk Patoloji
Derg. 2011;27:169-72.
17) Cronje HS, Woodruff DW. Primary ovarian malignant melanoma
arising in a cystic teratoma. Gynecol Oncol. 1981; 12:379-83.
18) McCluggage WG, Bissonnette JP, Young RH. Primary malignant
melanoma of the ovary: A report of 9 definite or probable cases
with emphasis on their morphologic diversity and mimicry of
other primary and secondary ovarian neoplasms. Int J Gynecol
Pathol. 2006; 25:321-9.
19) Scully RE. Tumors of the ovary and maldeveloped gonads.
Washington, DC: Armed Forces Institute of Pathology; 1979.
255-63.